시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 B형 간염 바이러스(HBV) 캡시드 억제제 시장 보고서(2025년)
Hepatitis B Virus (HBV) Capsid Inhibitors Global Market Report 2025
상품코드 : 1889397
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,573,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,501,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,429,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

B형 간염 바이러스(HBV) 캡시드 억제제 시장 규모는 최근 급속히 확대되고 있습니다. 2024년 4억 6,000만 달러에서 2025년에는 5억 2,000만 달러로, CAGR 13.8%로 성장하였습니다. 지난 수년간의 성장은 HBV 캡시드 조립 조절제에 초점을 맞춘 임상 검사 증가, 국가 예방 접종 프로그램 및 건강 모니터링 프로그램과 HBV의 통합 확대, 캡시드 억제제의 효능을 뒷받침하는 임상 데이터의 발표 증가, HBV의 예방 및 관리를 촉진하는 세계적인 계발 활동 강화, 고급 분자 모델링 등이 요인입니다.

B형 간염 바이러스(HBV) 캡시드 억제제 시장 규모는 향후 수년간 급속한 성장이 예상됩니다. 2029년에는 8억 6,000만 달러에 달하고 CAGR은 13.5%를 나타낼 것으로 예측됩니다. 예측기간의 성장은 병용요법에 대한 수요 증가, 임상검사의 고도단계로 진행되는 파이프라인 제품 증가, 만성 HBV 감염에 대한 환자의 인식도와 스크리닝 향상, 바이러스 내성을 표적으로 한 맞춤형 치료 접근법의 채용 확대, 임상 모니터링과 치료 준수용 디지털 플랫폼의 활용 확대에 의해 견인될 전망입니다. 예측기간의 주요 동향으로는 임상검사단계가 진전하고 있는 차세대 캡시드 조립제의 개발, 캡시드 억제제 및 면역조절제와 cccDNA 표적약제를 조합한 고급 병용요법의 개발, 환자의 복약 준수율 향상을 목적으로 한 혁신적인 경구 저분자 제제의 개발, 치료 선택의 지침이 되는 바이오마커와 동반진단의 통합, 차세대 분자를 포함한 내성 관리 및 예방 전략의 진전을 들 수 있습니다.

B형 간염 바이러스(HBV) 감염 증가 추세는 B형 간염 바이러스(HBV) 캡시드 억제제 시장의 성장을 가속할 것으로 예측됩니다. B형 간염 바이러스(HBV) 감염은 B형 간염 바이러스에 의한 간 감염이며 급성 및 만성 질환을 유발할 수 있습니다. 본 바이러스는 감염된 혈액이나 체액과의 접촉에 의해 확산되어 간경변이나 간암 등의 심각한 합병증을 일으킬 가능성이 있습니다. HBV 감염 증가 추세는 주로 백신접종률 저하에 기인하고 있으며, 인구의 대부분이 보호되지 않은 상태에 노출됨으로써 바이러스 전파가 촉진되고 있습니다. HBV 캡시드 억제제는 바이러스 캡시드의 형성과 조립을 억제함으로써 B형 간염의 치료에 기여하고, 바이러스 복제를 저지함과 동시에 체내에서의 감염 확산을 억제합니다. 예를 들어, 2024년 4월 스위스에 본부를 두고 있는 국제기구인 세계보건기구(WHO)는 2022년 말 만성 B형 간염 환자 중 단 13%가 진단을 받았으며 약 3%(700만 명)가 항바이러스 치료를 받고 있다고 보고했습니다. 이에 대해 C형 간염에서는 이환 환자의 36%가 진단되었고, 20%(1,250만명)가 근치적 치료를 받고 있으며, 2030년까지 만성 B형과 C형 간염 환자의 80% 치료를 목표로 하는 세계 기준에 크게 밑도는 수치입니다. 따라서 B형 간염 바이러스 감염 증가 추세는 HBV 캡시드 억제제 시장의 성장을 이끌고 있습니다.

HBV 캡시드 억제제 시장에서 사업을 전개하는 주요 기업은 항바이러스 효과 향상, 환자 복약 준수율 개선, 지속적인 바이러스 억제 달성을 목적으로 경구 투여 가능한 저분자 캡시드 조립 조절제 등의 기술 혁신 개발에 주력하고 있습니다. 경구 저분자 캡시드 조립 조절제는 B형 간염 바이러스 캡시드의 조립을 억제하고 체내 바이러스 복제를 차단하여 바이러스 활성을 감소시키는 경구 항바이러스제입니다. 예를 들어, 2024년 7월에는 미국에 거점을 두는 임상단계 바이오의약품기업인 Aligos Therapeutics사가 중국에 거점을 두는 바이오의약품기업인 Xiamen Amoytop Biotech사와 제휴해 만성 B형 간염(CHB)에 대한 혁신적인 치료 후보약을 평가하는 임상시험을 개시했습니다. 본 검사에서는 고급 캡시드 조립 조절 기술을 활용하여 항바이러스 효과의 향상과 차세대 HBV 치료법의 개발 가속화를 도모합니다. 이는 만성 B형 간염 환자에 대한 효과적이고 잠재적으로 근치적인 치료의 개발을 목표로 하는 Aligos사의 이니셔티브에서 중요한 단계입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장의 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 전략

제36장 부록

CSM
영문 목차

영문목차

Hepatitis B virus (HBV) capsid inhibitors are antiviral agents designed to interfere with the assembly, disassembly, or stability of the viral capsid, which is crucial for HBV replication. These inhibitors act on the core protein that forms the protective shell around the viral DNA, thereby preventing the creation of new infectious particles. By disrupting the capsid formation process, they help lower viral load and slow disease progression. HBV capsid inhibitors represent a promising therapeutic strategy for moving toward a functional cure for chronic hepatitis B infection.

The main drug types of hepatitis B virus (HBV) capsid inhibitors include core protein allosteric modulators (CpAMs), capsid assembly modulators, and others. HBV capsid inhibitors, also known as core protein allosteric modulators (CpAMs), are antiviral agents that target and disrupt capsid assembly or stability, thereby blocking HBV replication and decreasing viral activity. The applications include chronic hepatitis B, acute hepatitis B, and other related uses, and they are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels. End users include hospitals, clinics, research institutes, and other healthcare settings.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The hepatitis B virus (HBV) capsid inhibitors market research report is one of a series of new reports from The Business Research Company that provides hepatitis B virus (HBV) capsid inhibitors market statistics, including hepatitis B virus (HBV) capsid inhibitors industry global market size, regional shares, competitors with a hepatitis B virus (HBV) capsid inhibitors market share, detailed hepatitis B virus (HBV) capsid inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the hepatitis B virus (HBV) capsid inhibitors industry. This hepatitis B virus (HBV) capsid inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hepatitis B virus (HBV) capsid inhibitors market size has grown rapidly in recent years. It will grow from $0.46 billion in 2024 to $0.52 billion in 2025 at a compound annual growth rate (CAGR) of 13.8%. The growth in the historic period resulted from increasing clinical trials focused on HBV capsid assembly modulators, the rising inclusion of HBV in national immunization and health surveillance programs, growing publication of clinical data validating capsid inhibitor efficacy, heightened global awareness campaigns promoting HBV prevention and management, and the increasing adoption of advanced molecular modeling and drug design technologies.

The hepatitis B virus (HBV) capsid inhibitors market size is expected to see rapid growth in the next few years. It will grow to $0.86 billion in 2029 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period will be driven by rising demand for combination therapies, an increasing number of pipeline products entering advanced clinical trial phases, higher patient awareness and screening rates for chronic HBV infection, growing adoption of personalized treatment approaches targeting viral resistance, and expanding use of digital platforms for clinical monitoring and treatment adherence. Major trends in the forecast period include the advancement of next-generation capsid assembly modulators progressing through clinical trials, development of advanced combination regimens pairing capsid inhibitors with immune modulators and cccDNA-targeting agents, innovative oral small-molecule formulations designed to improve patient adherence, integration of biomarkers and companion diagnostics to guide therapy selection, and progress in strategies for managing and preventing resistance, including next-generation molecules.

The rising prevalence of hepatitis B virus (HBV) infections is expected to drive the growth of the hepatitis B virus (HBV) capsid inhibitors market. Hepatitis B virus (HBV) infections are liver infections caused by the hepatitis B virus, which can lead to both acute and chronic diseases. The virus spreads through contact with infected blood or bodily fluids and can result in serious complications such as liver cirrhosis or liver cancer. The increasing prevalence of HBV infections is largely attributed to low vaccination coverage, leaving significant portions of the population unprotected and facilitating virus transmission. HBV capsid inhibitors aid in treating hepatitis B infections by disrupting the formation and assembly of the viral capsid, thereby preventing viral replication and reducing the spread of infection within the body. For example, in April 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that as of the end of 2022, only 13% of individuals with chronic hepatitis B had been diagnosed, and approximately 3% (7 million) had received antiviral treatment. In comparison, for hepatitis C, 36% of affected individuals had been diagnosed, with 20% (12.5 million) receiving curative therapy, figures well below the global target of treating 80% of people living with chronic hepatitis B and C by 2030. Therefore, the increasing prevalence of hepatitis B virus infections is driving the growth of the HBV capsid inhibitors market.

Major companies operating in the HBV capsid inhibitors market are focusing on developing advancements such as oral small-molecule capsid assembly modulators to improve antiviral efficacy, patient compliance, and achieve sustained viral suppression. Oral small-molecule capsid assembly modulators are orally administered antiviral agents that interfere with the assembly of the hepatitis B virus capsid, blocking replication and reducing viral activity in the body. For instance, in July 2024, Aligos Therapeutics, Inc., a US-based clinical-stage biopharmaceutical company, collaborated with Xiamen Amoytop Biotech Co., Ltd., a China-based biopharmaceutical company, to launch a clinical trial evaluating innovative treatment candidates for chronic hepatitis B (CHB). The trial leverages advanced capsid assembly modulator technology to enhance antiviral efficacy and accelerate the development of next-generation HBV therapies, marking a significant step in Aligos's mission to develop effective and potentially curative treatments for chronic hepatitis B patients.

In October 2023, Gilead Sciences Inc., a US-based biopharmaceutical company, partnered with Assembly Biosciences Inc. to combine its antiviral expertise with Assembly Biosciences' innovative capsid inhibitor technology. The collaboration aims to accelerate the development of next-generation small-molecule antivirals that enhance viral suppression, improve treatment outcomes, and potentially achieve a functional cure for patients living with chronic hepatitis B infection. Assembly Biosciences Inc., based in the US, specializes in the discovery and development of antiviral therapeutics, including novel agents targeting hepatitis B virus and other viral infections.

Major companies operating in the hepatitis b virus (hbv) capsid inhibitors market are Johnson & Johnson, Roche Holding AG, GlaxoSmithKline plc, Gilead Sciences Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Novotech Health Holdings Pte. Ltd, Enanta Pharmaceuticals Inc., Assembly Biosciences Inc., Arbutus Biopharma Corporation, Aligos Therapeutics Inc., Qilu Pharmaceutical Co Ltd., Chia Tai Tianqing Pharmaceutical Group Co Ltd., Hepion Pharmaceuticals Inc., Shanghai Zhimeng Biopharma Inc., Antios Therapeutics, Bluejay Therapeutics Inc., Core Biopharma Inc., Door Pharmaceuticals, Shanghai Longwood Biopharmaceuticals Co. Ltd., Zhimeng Biopharma Inc.

Asia-Pacific was the largest region in the hepatitis B virus (HBV) capsid inhibitors market in 2024. The regions covered in hepatitis B virus (HBV) capsid inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hepatitis B virus (HBV) capsid inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hepatitis B virus (HBV) capsid inhibitors market consists of sales of vebicorvir, bepirovirsen, cavrotolimod, hepcludex, and morphothiadin. Values in this market are 'factory gate' values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hepatitis B Virus (HBV) Capsid Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hepatitis b virus (hbv) capsid inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for hepatitis b virus (hbv) capsid inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hepatitis b virus (hbv) capsid inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Hepatitis B Virus (HBV) Capsid Inhibitors Market Characteristics

3. Hepatitis B Virus (HBV) Capsid Inhibitors Market Trends And Strategies

4. Hepatitis B Virus (HBV) Capsid Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Hepatitis B Virus (HBV) Capsid Inhibitors Growth Analysis And Strategic Analysis Framework

6. Hepatitis B Virus (HBV) Capsid Inhibitors Market Segmentation

7. Hepatitis B Virus (HBV) Capsid Inhibitors Market Regional And Country Analysis

8. Asia-Pacific Hepatitis B Virus (HBV) Capsid Inhibitors Market

9. China Hepatitis B Virus (HBV) Capsid Inhibitors Market

10. India Hepatitis B Virus (HBV) Capsid Inhibitors Market

11. Japan Hepatitis B Virus (HBV) Capsid Inhibitors Market

12. Australia Hepatitis B Virus (HBV) Capsid Inhibitors Market

13. Indonesia Hepatitis B Virus (HBV) Capsid Inhibitors Market

14. South Korea Hepatitis B Virus (HBV) Capsid Inhibitors Market

15. Western Europe Hepatitis B Virus (HBV) Capsid Inhibitors Market

16. UK Hepatitis B Virus (HBV) Capsid Inhibitors Market

17. Germany Hepatitis B Virus (HBV) Capsid Inhibitors Market

18. France Hepatitis B Virus (HBV) Capsid Inhibitors Market

19. Italy Hepatitis B Virus (HBV) Capsid Inhibitors Market

20. Spain Hepatitis B Virus (HBV) Capsid Inhibitors Market

21. Eastern Europe Hepatitis B Virus (HBV) Capsid Inhibitors Market

22. Russia Hepatitis B Virus (HBV) Capsid Inhibitors Market

23. North America Hepatitis B Virus (HBV) Capsid Inhibitors Market

24. USA Hepatitis B Virus (HBV) Capsid Inhibitors Market

25. Canada Hepatitis B Virus (HBV) Capsid Inhibitors Market

26. South America Hepatitis B Virus (HBV) Capsid Inhibitors Market

27. Brazil Hepatitis B Virus (HBV) Capsid Inhibitors Market

28. Middle East Hepatitis B Virus (HBV) Capsid Inhibitors Market

29. Africa Hepatitis B Virus (HBV) Capsid Inhibitors Market

30. Hepatitis B Virus (HBV) Capsid Inhibitors Market Competitive Landscape And Company Profiles

31. Hepatitis B Virus (HBV) Capsid Inhibitors Market Other Major And Innovative Companies

32. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hepatitis B Virus (HBV) Capsid Inhibitors Market

34. Recent Developments In The Hepatitis B Virus (HBV) Capsid Inhibitors Market

35. Hepatitis B Virus (HBV) Capsid Inhibitors Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기